Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2

Canadian Journal of Physiology and Pharmacology

Volumn 81, Issue 11, 2003, Pages 1005-1012

  Brubaker, Patricia L ^a   Anini, Younes ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

GLP 1; GLP 2; Intestine; Neural; Nutrients; Secretion

Indexed keywords

GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; LEPTIN; SOMATOSTATIN;

EPITHELIUM CELL; HORMONE RELEASE; HUMAN; INTESTINE CELL; L CELL; NONHUMAN; NUTRIENT; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW;

ANIMALS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INTESTINAL MUCOSA; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN PRECURSORS; VAGUS NERVE;

EID: 0347990354     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y03-107     Document Type: Review

References (96)

1. Anini, Y., and Brubaker, P.L. 2003a. Muscaranic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology, 144: 3244-3250.
2. Anini, Y., and Brubaker, P.L. 2003b. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes, 52: 252-259.
3. Anini, Y., Fu-Cheng, X.M., Cuber, J.C., Kervran, A., Chariot, J., and Rozé, C. 1999. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch. 438: 299-306.
4. Anini, Y., Hansotia, T., and Brubaker, P.L. 2002. Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology, 143: 2420-2426.
5. Au, A., Gupta, A., Schembri, P., and Cheeseman, C.I. 2002. Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2. Biochem. J. 367: 247-254.
6. Balks, H.J., Holst, J.J., Von zur Mühlen, A., and Brabant, G. 1997. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: Cholinergic control of GLP-1 secretion via muscarinic receptors. J. Clin. Endocrinol. Metab. 82: 786-790.
7. Benjamin, M.A., McKay, D.M., Yang, P.C., Cameron, H., and Perdue, M.H. 2000. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut, 47: 112-119.
8. Beyse, C., Karpe, F., Fielding, B.A., Clark, A., Levy, J.C., and Frayn, K.N. 2002. Interaction between specific fatty acids, GLP-1 and insulin secretion in humans. Diabetologia, 45: 1533-1541.
9. Bloom, S.R., and Polak, J.M. 1982. The hormonal pattern of intestinal adaptation: a major role for enteroglucagon. Scand. J. Gastroenterol. 17(Suppl. 74): 93-103.
10. Boushey, R.P., Yusta, B., and Drucker, D.J. 1999. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am. J. Physiol. 277: E937-E947.
11. Brubaker, P.L. 1991. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology, 128: 3175-3182.
12. Brubaker, P.L., and Drucker, D.J. 2002. Structure-function of the glucagon receptor superfamily of receptors: the glucagon, GIP, GLP-1 and GLP-2 receptors. Receptors Channel, 8: 179-188.
13. Brubaker, P.L., Efendic, S., and Greenberg, G.R. 1997a. Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release. Endocrine, 6: 91-95.
14. Brubaker, P.L., Izzo, A., Hill, M., and Drucker, D.J. 1997b. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am. J. Physiol. 272: E1050-E1058.
15. Campos, R.V., Lee, Y.C., and Drucker, D.J. 1994. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology, 134: 2156-2164.
16. Chisholm, C., and Greenberg, G.R. 2002. Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. Am. J. Physiol. 283: E311-E317.
17. Damholt, A.B., Buchan, A.M., and Kofod, H. 1998. Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent insulinotropic peptide but unaffected by glucose. Endocrinology, 139: 2085-2091.
18. Dhanvantari, S., Seidah, N.G., and Brubaker, P.L. 1996. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol. Endocrinol. 10: 342-355.
19. Drucker, D.J. 2001. Glucagon-like peptide 2. J. Clin. Endocrinol. Metab. 86: 1759-1764.
20. Drucker, D.J. 2002. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology, 122: 531-544.
21. Drucker, D.J. 2003. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs, 12: 87-100.
22. Drucker, D.J., Ehrlich, P., Asa, S.L., and Brubaker, P.L. 1996. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. U.S.A. 93: 7911-7916.
23. Drucker, D.J., Shi, Q., Crivici, A., Sumner-Smith, M., Tavares, W., Hill, M., DeForest, L., Cooper, S., and Brubaker, P.L. 1997. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat. Biotechnol. 15: 673-677.
24. Dumoulin, V., Dakka, T., Plaisancie, P., Chayvialle, J.-A., and Cuber, J.-C. 1995. Regulation of glucagon-like peptide-1-(7-36)amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology, 136: 5182-5188.
25. Dumoulin, V., Moro, F., Barcelo, A., Dakka, T., and Cuber, J.C. 1998. Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology, 139: 3780-3786.
26. Eglen, R.M., Choppin, A., and Watson, N. 2001. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol. Sci. 22: 409-414.
27. Eissele, R., Göke, R., Willemer, S., Harthus, H.P., Vermeer, H., Arnold, R., and Göke, B. 1992. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Invest. 22: 283-291.
28. Ferraris, R.P., Yasharpour, S., Lloyd, K.C.K., Mirzayan, R., and Diamond, J.M. 1990. Luminal glucose concentrations in the gut under normal conditions. Am. J. Physiol. 259: G822-G837.
29. Fischer, K.D., Dhanvantari, S., Drucker, D.J., and Brubaker, P.L. 1997. Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats. Am. J. Physiol. 273: E815-E820.
30. Friedman, J.M., and Halaas, J.L. 1998. Leptin and the regulation of body weight in mammals. Nature (London), 395: 763-770.
31. Fu-Cheng, X., Anini, Y., Chariot, J., Castex, C., Galmiche, J.P., and Rozé, C. 1997. Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut. Pflugers Arch. 433: 571-579.
32. Fuessl, H.S., Burrin, J.M., Williams, G., Adrian, T.E., and Bloom, S.R. 1987. The effect of a long-acting somatostatin analogue (SMS 210-995) on intermediary metabolism and gut hormones after a test meal in normal subjects. Aliment. Pharmacol. Ther. 1: 321-330.
33. Greeley, G.H., Jeng, Y.J., Gomez, G., Hashimoto, T., Hill, F.L.C., Kern, K., Kurosky, T., Chuo, H.-F., and Thompson, J.C. 1989. Evidence for regulation of peptide-YY release by the proximal gut. Endocrinology, 124: 1438-1443.
34. Gremlich, S., Porret, A., Hani, E.H., Cherif, D., Vionnet, N., Froguel, P., and Thorens, B. 1995. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes, 44: 1202-1208.
35. Gribble, F.M., Williams, L., Simpson, A.K., and Reimann, F. 2003. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes, 52: 1147-1154.
36. Guan, X., Stoll, B., Lu, X., Tappenden, K.A., Holst, J.J., Hartmann, B., and Burrin, D.G. 2003. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology, 125: 136-147.
37. Guilmeau, S., Buyse, M., Tsocas, A., Laigneau, J.P., and Bado, A. 2003. Duodenal leptin stimulates cholecystokinin secretion: evidence of a positivie leptin-cholecystokinin feedback loop. Diabetes, 52: 1664-1672.
38. Hartmann, B., Thulesen, J., Kissow, H., Thulesen, S., Orskov, C., Ropke, C., Poulsen, SS., and Holst, J.J. 2000. Dipeptidyl peptidase IV inhibition enhances the intestinotropic effect of glucagon-like peptide-2 in rats and mice. Endocrinology, 141: 4013-4020.
39. Hermann-Rinke, C., Vöge, A., Hess, M., and Göke, B. 1995. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J. Endocrinol. 147: 25-31.
40. Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., and Göke, B. 1995. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion, 56: 117-126.
41. Hiroyoshi, M., Tateishi, K., Yasunami, Y., Maeshiro, K., Ono, J., Matsuoka, Y., and Ikeda, S. 1999. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes. Am. J. Gastroenterol. 94: 976-981.
42. Holst, J.J. 2002. Therapy of type 2 diabetes mellitus based on the actions of glucagon- like peptide-1. Diabetes-Metab. Res. Rev. 18: 430-441.
43. Irwin, D.M. 2002. Ancient duplications of the human proglucagon gene. Genomics, 79: 741-746.
44. Jeppesen, P.B., Hartmann, B., Hansen, B.S., Thulesen, J., Holst, J.J., and Mortensen, P.B. 1999. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut, 45: 559-563.
45. Jeppesen, P.B., Hartmann, B., Thulesen, J., Graff, J., Lohmann, J., Hansen, B.S., Tofteng, F., Poulsen, S.S., Madsen, J.L., Holst, J.J., and Mortensen, P.B. 2001. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology, 120: 806-815.
46. Kieffer, T.J., and Habener, J.L. 1999. The glucagon-like peptides. Endocr. Rev. 20: 876-913.
47. Kieffer, T.J., McIntosh, C.H.S., and Pederson, R.A. 1995. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 136: 3585-3596.
48. L'Heureux, M.-C., and Brubaker, P.L. 2001. Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2. Ann. Med. 33: 229-235.
49. L'Heureux, M.-C., and Brubaker, P.L. 2003. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J. Pharm. Exp. Ther. 306: 347-354.
50. Layer, P., Holst, J.J., Grandt, D., and Goebell, H. 1995. Ileal release of glucagon-like peptide-1 (GLP-1): association with inhibition of gastric acid secretion in humans. Dig. Dis. Sci. 40: 1074-1082.
51. Lee, Y.C., Brubaker, P.L., and Drucker, D.J. 1990. Developmental and tissue-specific regulation of proglucagon gene expression. Endocrinology, 127: 2217-2222.
52. Li, Y., and Owyang, C. 1993. Vagal afferent pathway mediates physiological action of cholecystokinin on pancreatic enzyme secretion. J. Clin. Invest. 92: 418-424.
53. Lovshin, J., Estall, J., Yusta, B., Brown, T.J., and Drucker, D.J. 2001. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J. Biol. Chem. 276: 21 489-21 499.
54. MacDonald, P.E., El-Kholy, W., Riedel, M.J., Salapatek, A.M., Light, P.E., and Wheeler, M.B. 2002. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes, 51(Suppl. 3): S434-S442.
55. Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Menucci, A., Pierazzuoli, E., Ciani, S., Fanelli, A., Messeri, G., and Rotella, C.M. 2000. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabetes Med. 17: 713-719.
56. Miyashita, T., Hashimoto, T., Gomez, G., Townsend, C.M., Jr., Greeley, G.H., Jr., and Thompson, J.C. 1992. Neurotensin secretion in response to intraduodenal and intraileal administration of fat in dogs. Biol. Signals 1: 275-281.
57. (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79: 616-619.
58. Morgan, L., Elliott, R., Tredger, J., Nightingale, J., and Marks, V. 1993. GLP-1 secretion in response to nutrients in man. Digestion, 54: 374-376.
59. Mortensen, K., Christensen, L.L., Holst, J.J., and Orskov, C. 2003. GLP-1 and GIP are colocalized ina subset of endocrine cells in the small intestine. Regul. Pept. 114: 189-196.
60. Nauck, M.A., Bartels, E., Orskov, C., Ebert, R., and Creutzfeldt, W. 1993. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76: 912-917.
61. Orskov, C., Holst, J.J., Knuhtsen, S., Baldissera, F.G.A., Poulsen, S.S., and Nielsen, O.V. 1986. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology, 119: 1467-1475.
62. Orskov, C., Andreasen, J., and Holst, J.J. 1992. All products of proglucagon are elevated in plasma from uremic patients. J. Clin. Endocrinol. Metab. 74: 379-384.
63. Persson, K., Gingerich, R.L., Nayak, S., Wada, K., Wada, E., and Ahren, B. 2000. Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. Am. J. Physiol. 279: E956-E962.
64. Plaisancié, P., Dumoulin, V., Chayvialle, J.-A., and Cuber, J.-C. 1995. Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon. J. Endocrinol. 145: 521-526.
65. Prigeon, R.L., Quddusi, S., Paty, B., and D'Alessio, D.A. 2003. Suppression of endogenous glucose production by glucagon-like peptide 1 independent of islet hormones: an extrapancreatic effect of an incretin hormone. Am. J. Physiol 285: E701-E707.
66. Qualmann, C., Nauck, M.A., Holst, J.J., Orskov, C., and Creutzfeldt, W. 1995. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut - a study using alpha-glucosidase inhibition (acarbose). Scand. J. Gastroenterol. 30: 892-896.
67. Ranganath, L., Norris, F., Morgan, L., Wright, J., and Marks, V. 1999. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids. Clin. Sci. (Lond.), 96: 335-342.
68. Rask, E., Olsson, T., Soderberg, S., Johnson, O., Secki, J., Holst, J.J., and Ahren, B. 2001. Impaired incretin response after a mixed meal is asociated with insulin resistance in nondiabetic men. Diabetes Care, 24: 1640-1645.
69. Reimann, F., and Gribble, F.M. 2002. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes, 51: 2757-2763.
70. Reimer, R.A., Darimont, C., Gremlich, S., Nicolas-Metral, V., Ruegg, U.T., and Mace, K. 2001. A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology, 142: 4522-4528.
71. Roberge, J.N., and Brubaker, P.L. 1991. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology, 128: 3169-3174.
72. Roberge, J.N., and Brubaker, P.L. 1993. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology, 133: 233-240.
73. Roberge, J.N., Gronau, K.A., and Brubaker, P.L. 1996. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology, 137: 2383-2388.
74. Robertson, M.D., Livesey, G., Morgan, L.M., Hampton, S.M., and Mathers, J.C. 1999. The influence of the colon on postprandial glucagon-like peptide 1 (7-36) amide concentration in man. J. Endocrinol. 161: 25-31.
75. Rocca, A.S., and Brubaker, P.L. 1995. Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. Endocrinology, 136: 5593-5599.
76. Rocca, A.S., and Brubaker, P.L. 1999. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology, 140: 1687-1694.
77. Rocca, A.S., LaGreca, J., Kalitsky, J., and Brubaker, P.L. 2001. Monounsaturated fatty acids improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology, 142: 1148-1155.
78. Rothenberg, M.E., Eilertson, C.D., Klein, K., Zhou, Y., Lindberg, I., McDonald, J.K., Mackin, R.B., and Noe, B.D. 1995. Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro. J. Biol. Chem. 270: 10 136-10 146.
79. Rouille, Y., Martin, S., and Steiner, D.F. 1995. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J. Biol. Chem. 270: 26 488-26 496.
80. Sasaki, H., Manaka, H., Yamatani, K., and Tominaga, M. 1993. GLP-1 secretion coupled with Na/glucose transporter from the isolated perfused canine ileum. Digestion, 54: 365-367.
81. Scott, R.B., Kirk, D., MacNaughton, W.K., and Meddings, J.B. 1998. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am. J. Physiol. 275: G911-G921.
82. Seifarth, C., Bergmann, J., Holst, J.J., Ritzel, R., Schmiegel, W., and Nauck, M.A. 1998. Prolonged and enhanced secretion of glucagon-like peptide 1(7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabetes Med. 15: 485-491.
83. Tavares, W., Drucker, D.J., and Brubaker, P.L. 2000. Enzymatic-and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am. J. Physiol. 278: E134-E139.
84. Toft-Nielsen, M.B., Madsbad, S., and Holst, J.J. 1999. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22: 1137-1143.
85. Tsai, C.H., Hill, M., and Drucker, D.J. 1997. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am. J. Physiol. 272: G662-G668.
86. Verdich, C., Toubro, S., Buemann, B., Lysgard Madsen, J., Holst, J.J., and Astrup, A. 2001. The role of postprandial release of insulinand incretin hormones in meal-induced satiety - effect of obesity and weight reduction. Int. J. Obes. Relat. Metab. Disord. 25: 1206-1214.
87. Vilsboll, T., Krarup, T., Deacon, C.F., Madsbad, S., and Holst, J.J. 2001. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 50: 609-613.
88. Vilsboll, T., Krarup, T., Madsbad, S., and Holst, J.J. 2003. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 114: 115-121.
89. Wang, Q., and Brubaker, P.L. 2002. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia, 45: 1263-1273.
90. White, J.W., and Saunders, G.F. 1986. Structure of the human glucagon gene. Nucleic Acids Res. 14: 4719-4730.
91. Willms, B., Werner, J., Holst, J.J., Orskov, C., Creutzfeldt, W., and Nauck, M.A. 1996. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 81: 327-332.
92. Xiao, Q., Boushey, R., Drucker, D.J., and Brubaker, P.L. 1999. Secretion of the intestinotropic hormone glucagon-like peptide-2 is differentially regulated by nutrients in humans. Gastroenterology, 117: 99-105.
93. Xiao, Q., Boushey, R.P., Cino, M., Drucker, D.J., and Brubaker, P.L. 2000. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am. J. Physiol. 278: R1057-R1063.
94. Xu, G., Stoffers, D.A., Habener, J.F., and Bonner-Weir, S. 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes, 48: 2270-2276.
95. Zander, M., Madsbad, S., Madsen, J.L., and Holst, J.J. 2002. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet, 359: 824-830.
96. Zhu, J.X., Wu, X.Y., Owyang, C., and Li, Y. 2001. Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat. J. Physiol. 530: 431-442.